Search Results

You are looking at 1 - 10 of 48 items for :

Clear All
Open access

Gudmundur Johannsson, Martin Bidlingmaier, Beverly M K Biller, Margaret Boguszewski, Felipe F Casanueva, Philippe Chanson, Peter E Clayton, Catherine S Choong, David Clemmons, Mehul Dattani, Jan Frystyk, Ken Ho, Andrew R Hoffman, Reiko Horikawa, Anders Juul, John J Kopchick, Xiaoping Luo, Sebastian Neggers, Irene Netchine, Daniel S Olsson, Sally Radovick, Ron Rosenfeld, Richard J Ross, Katharina Schilbach, Paulo Solberg, Christian Strasburger, Peter Trainer, Kevin C J Yuen, Kerstin Wickstrom, Jens O L Jorgensen and on behalf of the Growth Hormone Research Society

factor-I (IGF-I). Both are used diagnostically; IGF-I is used to monitor the effects of GH replacement in GH deficiency (GHD), and both GH and IGF-I are used in the diagnosis and management of acromegaly. While serum IGF-I level is used as a surrogate

Open access

Urszula Smyczyńska, Joanna Smyczyńska, Maciej Hilczer, Renata Stawerska, Ryszard Tadeusiewicz and Andrzej Lewiński

), in some of them also concentrations of IGF-I ( 7 , 8 , 9 , 13 ) and IGFBP-3 ( 7 , 9 ) have been processed. The most frequently used method of deriving models of GH therapy outcomes has been multiple linear regression (MLR) ( 6 , 7 , 10 , 11

Open access

M Krause, H Frederiksen, K Sundberg, F S Jørgensen, L N Jensen, P Nørgaard, C Jørgensen, P Ertberg, J H Petersen, U Feldt-Rasmussen, A Juul, K T Drzewiecki, N E Skakkebaek and A M Andersson

factor I (IGF-I) and its major binding protein: insulin-like growth factor-binding protein-3 (IGFBP3). IGF-I and IGFBP3 were both measured by a chemiluminescence immunoassay on the IDS-iSYS automated platform (Immuno Diagnostic Systems, IDS) at the

Open access

Werner F Blum, Abdullah Alherbish, Afaf Alsagheir, Ahmed El Awwa, Walid Kaplan, Ekaterina Koledova and Martin O Savage

Introduction The growth hormone (GH)–insulin-like growth factor (IGF)-I axis is the principle endocrine system regulating linear growth in children ( 1 ). Linked to the nutritional status of the individual, GH is a potent stimulator of IGF-I

Open access

Alessandro Ciresi, Stefano Radellini, Valentina Guarnotta, Maria Grazia Mineo and Carla Giordano

one of the most influential regulators of growth hormone (GH) secretion and action, with different mechanisms ( 2 ). Androgens and estrogens exert opposite endocrine-mediated effects on insulin-like growth factor (IGF)-I production and metabolic

Open access

Juliane Léger, Anne Fjellestad-Paulsen, Anne Bargiacchi, Catherine Doyen, Emmanuel Ecosse, Jean-Claude Carel and Marie-France Le Heuzey

involving the growth hormone (GH)-insulin-like growth factor-I (IGF-I) axis, thyroid function, hypercortisolemia, hypogonadotropic hypogonadism and the levels of several adipokines and gut peptides, such as ghrelin and peptide YY ( 2 ). The

Open access

Robert Rapaport, Peter A Lee, Judith L Ross, Paul Saenger, Vlady Ostrow and Giuseppe Piccoli

(eg, HSDS, age, insulin-like growth factor 1 (IGF-I) SDS) on changes in HSDS in response to GH therapy over time ( 12 , 13 ). The analysis described here evaluated growth outcomes (HSDS, IGF-I SDS and BMI SDS), bone age per chronological age (BA

Open access

K L Gatford, G K Heinemann, S D Thompson, J V Zhang, S Buckberry, J A Owens, G A Dekker, C T Roberts and on behalf of the SCOPE Consortium

Khosravi MJ Diamandis A van Doorn J Juul A . Insulin-like growth factors (IGF-I, free IGF-I, and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation . Journal of Clinical Laboratory

Open access

Louise Færch, Anders Juul, Ulrik Pedersen-Bjergaard and Birger Thorsteinsson

P Mathiesen ER . Lower levels of circulating IGF-I in type 1 diabetic women with frequent severe hypoglycaemia during pregnancy . Diabetic Medicine 2008 25 826 – 833 . ( doi:10.1111/j.1464-5491.2008.02495.x ). 6 Tan K Baxter RC . Serum

Open access

A J Varewijck, A J van der Lely, S J C M M Neggers, S W J Lamberts, L J Hofland and J A M J L Janssen

to thank P Uitterlinden (Erasmus MC, Rotterdam, The Netherlands) for performing the immunoassays. References 1 Clemmons DR . IGF-I assays: current assay methodologies and their limitations . Pituitary 2007 10 121 – 128 . ( doi:10.1007/s11102